ABI-H2158

DRUG3 trials

Sponsors

Assembly Biosciences

Conditions

Chronic Hepatitis B

Phase 1

A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

CompletedNCT03714152

Assembly BiosciencesChronic Hepatitis B

Start: 2018-11-13End: 2021-01-07Updated: 2021-01-27

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

CompletedNCT04142762

Assembly BiosciencesChronic Hepatitis B

Start: 2019-10-18End: 2020-01-29Updated: 2020-03-04

Phase 2

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

TerminatedNCT04398134

Assembly BiosciencesChronic Hepatitis B

Start: 2020-08-28End: 2021-12-28Updated: 2022-09-15

Related Papers

Safety, pharmacokinetics and antiviral activity of <scp>ABI‐H2158</scp>, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study

Journal of Viral Hepatitis2022-10-276 citations